Immediate-release tablets containing GABA API are processed by direct compression only when the milled active pharmaceutical ingredient demonstrates acceptable flow and compaction after particle-size control. A batch screened on an Alpine air jet sieve according to Ph. Eur. 2.9.38 to a d90 below 200 µm is weighed into a low-shear tumble blender. A representative pre-blend is composed of 60.0% w/w GABA API, 35.5% w/w microcrystalline cellulose PH-102, 3.0% w/w croscarmellose sodium, and 1.0% w/w colloidal silicon dioxide. The pre-blend is mixed at 12–15 rpm for 15 min. Magnesium stearate 0.5% w/w is then added and blended for 3 min. The final blend is required to achieve a bulk density between 0.35 g/cm³ and 0.55 g/cm³ and a Hausner ratio below 1.35 when tested by USP <1174>. Compression is carried out on a 10-station rotary tablet press with B-tooling at 8–15 kN. Tablets are sampled every 15 min for mass, thickness, and hardness. Hardness is maintained at 60–100 N. Friability is kept below 0.8% w/w after 100 rotations according to USP <1216>. Disintegration in purified water at 37±2°C should not exceed 10 min by USP <701>. Dissolution testing under USP <711> Apparatus II at 50 rpm in 900 mL purified water is used to verify release consistency. Direct compression is not appropriate when ambient relative humidity exceeds 60% because the zwitterionic API may sorb sufficient moisture to increase sticking on punch faces and reduce tabletability. The finished product is an immediate-release oral tablet intended for film coating with an aqueous hypromellose system if additional moisture protection is required.

How Does GABA API Behave during Aqueous Wet Granulation in a Top-Spray Fluid Bed?

When direct compression cannot maintain content uniformity because of API cohesion or segregation, aqueous wet granulation is selected to densify the powder and stabilize the drug content distribution. A granulation charge is prepared with 70.0% w/w GABA API, 20.0% w/w lactose monohydrate, and 5.0% w/w intragranular croscarmellose sodium. A binder solution of povidone K30 at 5.0% w/w in purified water is sprayed onto the fluidized powder bed at 18–22% w/w of dry powder mass. The top-spray fluid-bed process runs with inlet air temperature 60–70°C, product temperature 28–32°C, atomization air pressure 1.0–1.5 bar, and spray rate 8–12 g/min/kg. The granulation endpoint is controlled by loss-on-drying at 1.5–2.0% w/w. Final drying reduces moisture to 0.8–1.2% w/w. The dried granules are milled through an 800 µm screen at 1500 rpm on a low-shear oscillating granulator. The resulting granule d50 is maintained between 120 µm and 180 µm. Magnesium stearate 0.5% w/w is blended into the milled granules for 3 min before compression or sachet filling. Granules filled into sachets are controlled to a fill weight of 500 mg±5%. The sachet product is tested for water activity below 0.6 at 25°C by USP <922> to limit microbial growth risk. Dissolution testing by USP <711> Apparatus II at 50 rpm in 900 mL purified water verifies that the granulation route does not delay release. Elemental impurities are controlled under ICH Q3D. High-shear granulation is avoided when local process temperature exceeds 40°C because heat-sensitive batches may show binding and recrystallization faults. The terminal product is either a sachet granule for oral administration or a compression-ready granule for further tableting.

Filling GABA API into hard gelatin or HPMC capsules requires densified powder with low electrostatic charge and stable bulk density. A tamping-pin capsule filler with 5 tamping stations is set to a pin depth of 12–18 mm for size 3 capsules. The encapsulated blend contains 55.0% w/w GABA API, 39.5% w/w lactose monohydrate, 5.0% w/w croscarmellose sodium, and 0.5% w/w magnesium stearate. Prior to filling, the blend is passed through a 600 µm mesh screen and tested for bulk density 0.40–0.60 g/cm³, tapped density 0.50–0.75 g/cm³, and Carr index below 20 by Ph. Eur. 2.9.36. Fill weight is controlled at 250 mg for size 3 capsules. Weight uniformity acceptance per USP <905> is maintained with RSD below 3.0%. The filling room is maintained at 20–25°C and 40–50% RH. Gelatin capsules become brittle below 40% RH and soften above 65% RH. HPMC capsules are selected when low residual moisture below 2.0% w/w is required. Static charge is controlled with ionizing bars and grounding straps on the filling machine. Final capsule dissolution is conducted by USP <711> Apparatus II in 900 mL purified water at 50 rpm. Disintegration is assessed by USP <701> and should not exceed 10 min in purified water at 37±2°C. Packaging in aluminum-PVC/PVDC blister is performed when moisture vapor transmission rate is below 0.5 g/m²/24h at 38°C and 90% RH. The final product is an immediate-release hard capsule dosage form.

Table 1 compares critical process thresholds for oral solid dosage forms across direct compression, aqueous wet granulation, and capsule filling.

Lyophilized Injectable Dose Forms and the Collapse Temperature Limit

For lyophilized parenteral presentations, injectable GABA API is processed into a sterile freeze-dried cake when aqueous solution stability is insufficient for ready-to-use storage. A formulation composed of 100 mg GABA API, 200 mg mannitol, and 50 mg trehalose dihydrate per vial is dissolved in Water for Injection at 5±3°C. The solution is filtered through a 0.22 µm PVDF membrane and filled into 10 mL Type I borosilicate glass vials to a fill volume of 5.0 mL. Vials are partially stoppered and loaded into a shelf freeze dryer with thermocouple probes. Freezing is carried out at −40°C for 120 min. Primary drying is conducted at −20°C and 80 µbar for 24 h. Secondary drying is performed at 25°C and 50 µbar for 6 h. The collapse temperature of the formulation must be determined by freeze-drying microscopy because published data for this specific GABA configuration is limited. The finished cake is tested for residual moisture by Karl Fischer titration according to USP <921> and must be below 1.0% w/w. Bacterial endotoxins are tested by USP <85> with a limit of <0.50 EU/mg. Particulate matter for injections must meet USP <788> limits. Sterility testing follows USP <71>. The lyophilized product is reconstituted with 5.0 mL Water for Injection and should produce a clear solution within 2 min. The final product is a sterile lyophilized powder for injection intended for reconstitution before parenteral administration.

In oral liquid manufacturing, a 20 mg/mL aqueous solution is compounded by dissolving GABA API in 80% of the final volume of purified water at 20–25°C under gentle stirring. A preservative system of sodium benzoate 0.1% w/v and citric acid monohydrate 0.05% w/v is added. Sucralose 0.1% w/v is used as a non-ionic sweetener. The pH is adjusted to 4.5–5.5 with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide. The batch is made to final volume with purified water and filtered through a 5 µm clarifying filter. Clarity is assessed according to Ph. Eur. 2.2.1. Visible particles are controlled by Ph. Eur. 2.9.20. The solution is filled into amber Type III glass bottles with child-resistant closures. Antimicrobial effectiveness testing is performed according to USP <51>. Assay of GABA API is carried out by HPLC with UV detection at 210 nm. Residual solvents must meet ICH Q3C limits. Elemental impurities are controlled by ICH Q3D. The final product is an oral solution at 20 mg/mL. If an oral suspension is required, a thixotropic vehicle based on microcrystalline cellulose and carboxymethylcellulose sodium is used, and the API particle size is controlled to d90 below 100 µm to ensure dose uniformity after shaking.

When Sterile Filtration Precedes Filling of a Ready-to-Use GABA Injection

Manufacture of a ready-to-use injectable solution is performed when the API is intended for parenteral administration in a hospital setting. The formulation consists of GABA API 5.0 g/L, sodium chloride 8.5 g/L, and Water for Injection to 1 L. The pH is adjusted to 6.0±0.2 with 0.1 M sodium hydroxide or hydrochloric acid. Compounding is performed in a Grade C cleanroom. The solution is pre-filtered through a 0.45 µm PES membrane and then sterilized by filtration through a 0.22 µm PES membrane. Filter integrity testing is performed before and after filtration according to ASTM F838-20. The filtered solution is filled aseptically into 10 mL Type I borosilicate glass ampoules or vials under Grade A laminar airflow. Fill volume is 5.2 mL. Headspace is purged with nitrogen to reduce oxidative stress. Terminal sterilization at 121°C for 15 min should not be introduced without forced degradation studies according to ICH Q1A because aqueous amino acid drug substances may degrade under thermal stress. The finished injection is tested for osmolality by USP <785>, with a specification of 280–320 mOsm/kg. Bacterial endotoxins are controlled by USP <85> with a limit of <0.50 EU/mL. Subvisible particulate matter must meet USP <788> for small-volume injections. Sterility is verified by USP <71>. The final product is a ready-to-use solution for injection.